Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells and generate lasting remission.
Umoja Biopharma is a clinical-stage biotechnology company pioneering in vivo CAR T cell therapy. Rather than manufacturing CAR T cells outside the body, Umoja's proprietary platform reprograms T cells inside patients, eliminating the costly and time-consuming ex vivo manufacturing process. The company's integrated technology platform is designed to make next-generation immunotherapy cost-effectively accessible to all cancer patients, including those who cannot benefit from current CAR T treatments. Umoja's pipeline targets solid tumors and hematologic malignancies.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2025
Jun 2021
Nov 2020
Feb 2019
Create a free account to see which investors have funded this company.
Create Free Account
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
